# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0190 |
| Population Package | PP-0190 |
| Title | Biomarker-Directed Treatment Selection |
| Version | 1.0.0 |
| Review Status | PASS |
| Production Status | GOLD |

---

# Layer 1 — Content QA

| Criterion | Result | QA Note |
|---|---|---|
| Single educational question | PASS | The package answers how biomarker results help determine which targeted treatment options may be considered. |
| Scope respected | PASS | The package is a treatment-selection bridge rather than a biomarker-testing or drug-management package. |
| Complete coverage | PASS | Actionability, treatment context, treatment line, biomarker branches, representative actionable biomarkers, combinations, limitations and patient questions are covered. |
| Internal consistency | PASS | CKO, KP and Evidence Package use the same core treatment-selection logic and boundaries. |
| Logical organization | PASS | Content follows biomarker result → actionability → clinical context → treatment relevance → treatment-selection discussion. |
| Patient-facing explanation complete | PASS | Concepts are explained without converting them into individualized treatment advice. |
| HER2 pathway covered | PASS | HER2 is treated as a primary treatment-selection example with upstream/downstream ownership preserved. |
| CLDN18.2 pathway covered | PASS | CLDN18.2 is treated as a primary treatment-selection example with clinical-setting dependence preserved. |
| Selected rare actionable biomarkers covered | PASS | NTRK, BRAF V600E and RET are included as selected molecular-treatment examples. |
| Immunotherapy boundary preserved | PASS | PD-L1, MSI-H/dMMR and TMB are cross-referenced without duplicating PP-0191. |
| Multiple-biomarker concept covered | PASS | Package explains integrated interpretation without inventing a universal biomarker priority order. |
| Positive/negative interpretation covered | PASS | Positive and negative results are explained as treatment-pathway implications rather than automatic prescriptions. |
| Common misconceptions addressed | PASS | At least the major actionability, positivity, negativity, treatment-line and targeted-vs-immunotherapy misconceptions are explicitly addressed. |
| Knowledge Graph complete | PASS | Prerequisite, related and downstream relationships are defined. |
| Boundary ownership controlled | PASS | Core / Supporting / Explicitly Excluded / Delegated-to PP boundaries are consistent with adjacent packages. |

---

# Layer 2 — Clinical QA

| Criterion | Result | QA Note |
|---|---|---|
| Source-grounded clinical content | PASS | Major clinical claims are anchored to the supplied NCCN, NCI and ACS materials. |
| Current NCCN version used as primary guideline | PASS | NCCN Gastric Cancer Version 2.2026 is the primary disease-specific guideline source. |
| HER2 treatment pathway accurately represented | PASS | First-line trastuzumab-containing treatment and later-line fam-trastuzumab deruxtecan are represented within defined advanced-disease contexts. |
| CLDN18.2 treatment pathway accurately represented | PASS | Zolbetuximab-containing treatment is represented in the defined CLDN18.2-positive advanced-disease context. |
| NTRK treatment pathway accurately represented | PASS | NTRK fusion-positive tumors are described as selected circumstances for TRK-directed treatment. |
| BRAF V600E pathway accurately represented | PASS | Dabrafenib/trametinib is described as a selected treatment option rather than universal therapy. |
| RET pathway accurately represented | PASS | Selpercatinib is described as a selected treatment option for RET fusion-positive tumors. |
| Treatment-line dependence represented | PASS | Later-line treatment is explicitly described as dependent on prior therapy and performance status. |
| Clinical-setting dependence represented | PASS | Biomarker status is not treated as independent of disease setting. |
| Combination treatment represented accurately | PASS | Targeted therapy is described as potentially combined with chemotherapy or other systemic treatment where source-supported. |
| Immunotherapy branch separated | PASS | PD-L1, MSI-H/dMMR and TMB are not converted into a duplicate immunotherapy package. |
| No unsupported universal algorithm | PASS | The package explicitly limits rare/emerging biomarker claims and does not construct an unsupported all-mutations treatment algorithm. |
| No individualized treatment recommendation | PASS | No patient-specific treatment instruction is given. |
| No unsafe treatment-change instruction | PASS | Package directs individualized decisions to the oncology team. |
| Actionability appropriately qualified | PASS | Actionability is presented as context-dependent rather than equivalent to automatic treatment eligibility. |
| Negative-result interpretation appropriately qualified | PASS | Negative biomarker status is not equated with absence of all treatment options. |
| NGS role appropriately bounded | PASS | NGS is treated as a testing approach; detailed NGS remains delegated. |
| ctDNA role appropriately bounded | PASS | ctDNA is acknowledged as a possible source of actionable genomic information without expanding into ctDNA methodology or monitoring. |

---

# Layer 3 — Educational QA

| Criterion | Result | QA Note |
|---|---|---|
| Plain language | PASS | Technical terms are introduced with patient-facing explanations. |
| Patient-friendly wording | PASS | The package uses questions, conceptual sequences and practical examples. |
| Learning objectives satisfied | PASS | Objectives map directly to the clinical knowledge blocks and key messages. |
| Learning progression coherent | PASS | The reader moves from biomarker result to actionability, clinical setting, treatment line and decision. |
| Actionability explained clearly | PASS | Detection, actionability, eligibility and treatment decision are separated. |
| Treatment-line concept clear | PASS | First-line and later-line concepts are explained without turning the package into a treatment algorithm. |
| Biomarker examples practical | PASS | HER2 and CLDN18.2 are used as primary examples; NTRK/BRAF/RET as selected examples. |
| Immunotherapy distinction clear | PASS | The targeted-treatment and immunotherapy branches are explicitly distinguished. |
| Patient questions useful | PASS | A structured question set is included for discussions with the care team. |
| Uncertainty appropriately communicated | PASS | Rare findings, actionability and clinical applicability are qualified. |
| Avoids overpromising | PASS | No guarantee of response is made from a biomarker result. |
| Encourages clinician discussion | PASS | Individualized decisions are repeatedly returned to the treating oncology team. |
| Appropriate educational boundary | PASS | No attempt is made to interpret an individual patient's actual biomarker result or prescribe treatment. |

---

# Layer 4 — Governance QA

| Criterion | Result | QA Note |
|---|---|---|
| CKO completed | PASS | 01_CKO.md produced. |
| Knowledge Passport completed | PASS | 02_KNOWLEDGE_PASSPORT.md produced. |
| Evidence Package completed | PASS | 03_PRIMARY_EVIDENCE_PACKAGE.md produced. |
| QA Report completed | PASS | This artifact completed. |
| Gold specification followed | PASS | Four-artifact structure preserved. |
| Approved Decision Batch respected | PASS | PP-0190 locked scope is implemented without reopening the decision. |
| Source-first rule respected | PASS | Project Source Files were searched before production. |
| Gold reference depth preserved | PASS | Artifacts were produced at full Gold depth rather than compacted. |
| Artifact naming compliant | PASS | Standard four artifact names used. |
| Versioning compliant | PASS | Semantic version 1.0.0 used. |
| Knowledge Graph complete | PASS | Prerequisite, related and downstream links included. |
| Boundary ownership preserved | PASS | Core / Supporting / Explicitly Excluded / Delegated-to PP structure used. |
| ZIP packaging compliant | PASS | Four Markdown artifacts packaged as one PP-specific ZIP. |
| Repository-ready structure | PASS | Package directory and artifact names follow the established Gold pattern. |

---

# Clinical Safety Review

| Item | Result | QA Note |
|---|---|---|
| No individualized treatment recommendation | PASS | Package explains treatment-selection principles only. |
| No instruction to start/stop/change treatment | PASS | Explicitly excluded. |
| No individualized prognosis | PASS | Explicitly excluded. |
| No individualized biomarker interpretation | PASS | Detailed interpretation remains upstream/dedicated. |
| No unsupported biomarker threshold | PASS | Detailed testing thresholds remain in dedicated biomarker packages; only source-supported treatment-defining context is described. |
| No universal claim that every mutation is actionable | PASS | Rare/emerging alterations are explicitly qualified. |
| No universal claim that positive means treatment | PASS | Positive result is presented as opening a potential pathway. |
| No universal claim that negative means no treatment | PASS | Negative result is presented as closing/reducing support for a particular pathway only. |
| No universal treatment algorithm | PASS | Full treatment sequencing remains downstream. |
| No claim that targeted therapy replaces chemotherapy | PASS | Combination use is explicitly preserved where source-supported. |
| No claim that biomarkers replace clinical judgment | PASS | Multidisciplinary/shared clinical decision-making is retained. |
| Targeted versus immunotherapy boundary preserved | PASS | PP-0191 remains owner of immunotherapy biomarker-selection content. |
| Upstream/downstream ownership preserved | PASS | Testing, report literacy, treatment selection and treatment-specific packages remain distinct. |

---

# Boundary QA

## Core

**Biomarker-directed targeted-treatment selection:** the clinical bridge from validated biomarker result to treatment relevance, including actionability, treatment-setting and treatment-line dependence, multiple-biomarker integration, positive/negative result implications, and representative HER2, CLDN18.2, NTRK, BRAF V600E and RET pathways.

## Supporting

Companion-diagnostic concept, molecular tumor board/multidisciplinary review, clinical-trial relevance, ctDNA-derived actionable findings at a conceptual level, and distinction between targeted and immunotherapy biomarker branches.

## Explicitly Excluded

Detailed biomarker testing/scoring, NGS methodology, variant interpretation/classification, molecular-report literacy, detailed ctDNA biology/monitoring, general treatment-by-stage algorithms, non-biomarker chemotherapy/surgery/radiotherapy selection, detailed immunotherapy selection, drug dosing/administration/toxicity management, treatment response/resistance management, and individualized treatment recommendations.

## Delegated-to PP

PP-0181, PP-0182, PP-0183, PP-0184, PP-0185, PP-0186, PP-0187, PP-0189, PP-0191, PP-0208, PP-0209, PP-0210, PP-0211, dedicated ctDNA/liquid-biopsy packages, and subsequent therapy-specific PPs according to the Project Coordinator's authoritative package list.

**Boundary QA result: PASS.**

---

# Evidence Traceability QA

## Primary Guideline

**Gastric Cancer v2.2026 — NCCN Clinical Practice Guidelines in Oncology**

Primary evidence for:

- biomarker testing framework;
- HER2 treatment selection;
- CLDN18.2 treatment selection;
- NTRK;
- BRAF V600E;
- RET;
- treatment-line dependence;
- performance-status dependence;
- molecularly targeted treatment architecture.

Relevant source locations include:

- GAST-1 / GAST-1A — biomarker work-up;
- GAST-B 3–7 — biomarker testing;
- GAST-F 4–5 — systemic therapy;
- MS-31 onward — targeted-therapy evidence discussion.

## NCI

**Treatment of Stomach Cancer**

Supports patient-facing targeted-treatment and biomarker-testing concepts.

**Gastric Cancer Treatment PDQ**

Supports professional treatment pathways and biomarker-linked treatment examples.

**Drugs Approved for Stomach (Gastric) Cancer**

Supports treatment/regulatory context for approved gastric-cancer agents.

## ACS

**Stomach Cancer**

Supports patient-facing targeted-treatment explanations for:

- HER2;
- CLDN18.2;
- TRK/NTRK;
- RET;
- BRAF.

**Immunotherapy for Stomach Cancer**

Supports separation of immunotherapy from targeted-treatment education.

## ESMO-ASCO

**Recommendations for a Global Curriculum in Medical Oncology — Edition 2023**

Supports the professional principle that predictive biomarkers should be interpreted and used in forming treatment plans and that molecular findings are part of broader clinical management.

---

# Evidence Consistency Review

No material conflict was identified between the supplied major evidence sources for the locked PP-0190 scope.

### NCCN

Provides the highest-priority gastric-cancer-specific treatment framework.

### NCI

Provides professional and patient-facing treatment context.

### ACS

Provides patient-facing explanations and representative targeted-treatment examples.

### ESMO-ASCO

Provides cross-cutting oncology education around predictive biomarkers and treatment planning.

The package uses NCCN as the primary disease-specific authority and the other sources as complementary evidence.

---

# Evidence Gap Review

The following limitations remain explicitly acknowledged:

1. Not every possible molecular alteration has an established gastric-cancer treatment pathway.
2. Rare and emerging biomarkers may change as evidence and regulatory/guideline recommendations evolve.
3. Exact treatment applicability requires individual clinical context.
4. Treatment availability varies by jurisdiction and time.
5. Detailed companion-diagnostic requirements are distributed across dedicated packages.
6. Multiple simultaneous biomarkers do not have a universal priority algorithm supported by the supplied sources.
7. Individualized treatment decisions require the treating oncology team and the complete clinical record.

No gap blocks the locked educational scope.

---

# Gold Artifact Completeness Check

| Artifact | Present | Structural QA |
|---|---|---|
| 01_CKO.md | PASS | Metadata, objectives, scope, included/not included, clinical knowledge blocks, patient explanation, clinical importance, key concepts, misconceptions, key messages, Knowledge Graph, patient questions, safety boundary and revision history present |
| 02_KNOWLEDGE_PASSPORT.md | PASS | Identity, classification, patient journey, runtime relevance, retrieval terms, Knowledge Graph, scope ownership, sources, evidence classification, governance and versioning present |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | PASS | Clinical question, scope, primary sources, evidence hierarchy, evidence matrix, evidence notes, consistency review, gaps, boundary verification, delegation and versioning present |
| 04_QA_REPORT.md | PASS | Four QA layers, clinical safety, boundary QA, evidence traceability, evidence gaps, completeness and final decision present |

---

# Gold Depth / Production Integrity Check

| Gold Requirement | Result | QA Note |
|---|---|---|
| Full-depth production | PASS | No artifact was intentionally compacted or summarized relative to the approved Gold reference standard. |
| Patient-facing depth | PASS | Explanatory blocks and misconceptions are developed at full educational depth. |
| Evidence depth | PASS | Evidence hierarchy, matrix, notes, gaps and traceability are included. |
| Knowledge Graph depth | PASS | Prerequisite, related, downstream and boundary relationships are explicit. |
| Boundary depth | PASS | Ownership is defined across Core, Supporting, Explicitly Excluded and Delegated-to PP. |
| QA depth | PASS | Content, clinical, educational, governance, safety, boundary and traceability layers are included. |
| Source-first integrity | PASS | Production is based on project Source Files and approved Gold references. |
| No silent scope expansion | PASS | Immunotherapy, detailed testing, drug management and individualized treatment remain outside ownership. |

---

# Final Quality Decision

# PASS

PP-0190 satisfies the locked **FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1** and the approved/locked PP-0190 Decision Batch.

The package maintains the intended architecture:

**Biomarker Testing**

↓

**Biomarker Result / Molecular Report**

↓

**PP-0190 — Biomarker-Directed Treatment Selection**

↓

**Targeted Therapy**

↓

**Therapy-Specific Treatment Packages**

with a parallel branch:

**Biomarker Result**

↓

**PP-0191 — Biomarker-Directed Immunotherapy Selection**

The package does not duplicate substantive ownership of:

- biomarker testing;
- molecular-report literacy;
- NGS methodology;
- variant interpretation;
- immunotherapy selection;
- targeted-therapy treatment management;
- therapy-specific drug packages.

The package preserves the central clinical safety principle:

> **A biomarker result informs treatment selection; it does not independently prescribe treatment.**

---

# Reviewer Notes

PP-0190 functions as a **clinical decision-bridge node** in the gastric-cancer precision-oncology Knowledge Graph.

Its principal value is to connect a validated biomarker result with the question that patients and clinicians actually face:

> **“Does this result change which treatment options should be considered?”**

The package deliberately avoids three unsafe shortcuts:

1. **Biomarker positive → automatic treatment.**
2. **Biomarker negative → no treatment options.**
3. **Actionable alteration → individualized treatment prescription.**

It also deliberately preserves the architecture:

**testing → result → treatment-selection bridge → treatment-specific package.**

This prevents duplication and maintains atomic ownership across the Population Package system.

---

# Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
